



Patent Technology Center 1600

Facsimile Transmission

To: Name: Mr. Truitt
 Company:
 Fax Number: 9-1-816-474-2150
 Voice Phone: 9-1-816-474-9050

From: Name:
 Official Fax Number: (571) 273-8300
 Official After Final Fax Number: (571) 273-8300
 Voice Phone:

37 C.F.R. 1.6 sets forth the types of correspondence that can be communicated to the Patent and Trademark Office via facsimile transmissions. Applicants are advised to use the certificate of facsimile transmission procedures when submitting a reply to a non-final or final Office action by facsimile (37 CFR 1.8(a)).

Fax Notes:

Mr. Truitt:

I have been trying to send this fax at 816-474-9057. It has been coming back as undelivered/ no response. I am sending it at this alternate number I got from your Office. If you receive the first one, Please ignore this one. Thank you.

Further to our telephone conversation of this morning, per your request, enclosed are the proposed amendments to Clams 1 and 12. I believe you were able to take notes for proposed amendments to dependent claims: 3-4, 6-9, 14-15, 17-20 and 22-24. Upon your approval, I will cancel Claims 1-51, rewrite the pending claims

Date and time of transmission: Thursday, July 14, 2005 3:02:30 PM
Number of pages including this cover sheet: 03

1. (Currently Amended) A method to determine the presence of an active Angiotensin Converting Enzyme-inhibiting drug (ACE-inhibiting drug) in a fluid sample, said drug in its active state modifies the activity level of an enzyme on a substrate, wherein said substrate is one among:.. , said method comprising the steps of:

- a. bringing a first fluid sample obtained from a patient, wherein said sample may or may not contain
said ACE-inhibiting drug, said first fluid sample being a serum or urine sample comprising said enzyme;
- b. adding a quantity of said substrate to said first fluid sample;
- c. measuring the activity level of said enzyme on said substrate;
- d. comparing said measured activity level with a standard activity level established by testing serum or urine samples that have a known quantity of active ACE-inhibiting drug present in said sample, wherein said standard samples are obtained from a plurality of individuals other than said patient; and
- e. determining the presence of said active ACE-inhibiting drug by said measured activity level.

12. (Currently Amended) A method of determining the presence of an active ACE- inhibiting drugs present in a fluid sample, said ACE-inhibiting drugs in their active state modifies the activity level of a target enzyme on a substrate, wherein said substrate is one among:.., said method comprising the steps of:

- a. bringing a first fluid sample obtained from a patient, wherein said sample may or may not contain
said ACE-inhibiting drug, said first fluid sample being a serum or urine sample;
- b. adding a quantity of said substrate to said first fluid sample;
- c. determining the activity level of said target enzyme on said selected substrate in said fluid sample at a first time to provide a base line activity level;
- d. comparing said measured activity level with a standard activity level established by testing serum or urine samples that have a known quantity of active ACE-inhibiting drugs

present in said sample, wherein said standard samples are obtained from a plurality of individuals other than said patient; and

- e. determining the concentration of said active ACE-inhibiting drugs in said first fluid sample.